Transition Care and Lifelong Monitoring
In 2026, "Transition Medicine" is a specialized field focused on the period when a GHD patient moves from pediatric to adult care. This is a critical stage where doctors must determine if the hormone deficiency was permanent or if the patient's pituitary function has normalized.
Patients undergo a "re-testing" phase after their height growth has finished. If the deficiency persists, the focus of therapy shifts from "growth" to "maintenance." Lifelong monitoring in 2026 involves regular DEXA scans to check bone density and lipid panels to monitor cardiovascular health. This holistic approach ensures that individuals with GHD can lead active, healthy lives, preventing the long-term complications of osteoporosis and heart disease that were common in previous generations.